Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 14, 2020

SELL
$3.16 - $6.73 $101,540 - $216,255
-32,133 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$4.1 - $8.05 $136,525 - $268,056
-33,299 Reduced 50.89%
32,133 $156,000
Q1 2019

May 15, 2019

BUY
$5.41 - $8.73 $353,987 - $571,221
65,432 New
65,432 $536,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $324M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Horizon Kinetics Asset Management LLC Portfolio

Follow Horizon Kinetics Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Horizon Kinetics Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Horizon Kinetics Asset Management LLC with notifications on news.